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HCC is now the third and fourth largest cause of cancer
mortality among males and females, respectively.5
However, several factors have an influence on the secular
mortality trends other than a real increase in mortality from
HCC. These include changes in classification systems and cod-
ing practices, diagnostic techniques and ascertainment, age
distribution, and survival from the disease.1,2,6–8 Although
monitoring trends of mortality can allow potential factors, which
influence both incidence and mortality, to be determined, no
published studies have analysed these factors in relation to the
trends of mortality from HCC in Japan. The purpose of this study
is to assess whether there was a real increase in mortality from
HCC and the factors that contributed to an increasing trend in
mortality from HCC during the past three decades in Japan.
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Background In Japan, higher mortality rates from hepatocellular carcinoma (HCC) have been
observed than in any other industrialized country and the reported numbers of
deaths due to HCC have increased significantly in recent years. We assessed
whether there was a real increase in mortality from HCC and which
factors contributed to the recent increasing trends of the number of deaths
from HCC.
Methods Poisson regression models were used to analyse panel data for the period
1972–2001.
Results In both sexes, age-standardized mortality rates from HCC increased significantly
over the past three decades. Among males the annual percentage increase in age-
adjusted mortality rates was approximately 1–3% during the period 1972–96.
On the other hand, female mortality trends were less clear. The estimated
birth cohort effects suggested that there was a peak in the mortality risk among
the cohorts born during the period 1927–36, which corresponded to those
aged between 50–64 years during the period 1987–96. This was the period
when a large increase of both age-specific mortality rates among older age
groups and age-standardized mortality rates were observed particularly
among males.
Conclusions This study shows that an upward trend of mortality from HCC in Japan was
primarily due to the effects among birth cohorts born around 1930, which are
consistent with the pattern of past exposure to hepatitis C virus. The cohort
effects have contributed to a large increase in mortality from HCC in recent years
and the number of deaths from HCC is expected to increase by 2010–15.
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Over the past decade, increase in the number of cases of
hepatocellular carcinoma (HCC) as well as deaths from it have
been reported in industrialized countries, including Japan, the
United States, and some European countries.1–3 In Japan,
higher mortality rates have been observed than in any other
industrialized country and the reported numbers of deaths due
to HCC have increased significantly in recent years.4 In Japan
Material and Methods
Data sources
Vital statistics data on the numbers of deaths from
hepatocellular carcinoma (HCC) and the estimates on age-
specific mid-year population for each calendar year from
1972 to 2001 were used for the analyses. Each death was
characterized by detailed demographic data including age at
death, year of death, and year of birth. We used the data on
mortality coded as 1550 for the period 1972–1994 (ICD-8 and
9) and C220 (ICD-10) for the period 1995–2001. In order to
make a comparison, we also analysed mortality from liver
cirrhosis (coded as 571 in the ICD-8 and 9, and K70 and 74 in
the ICD-10). The minimum age group for this study was
20–24 years. For men and women separately, the number of
deaths and populations were stratified by five-year age groups
(20–24, … , 85–89), five-year calendar periods (1972–76, … ,
1997–2001), and five-year birth cohorts (1882–86, … ,
1972–76). Data on incidence of post-transfusion hepatitis and
prevalence of hepatitis virus infections for the study periods
were obtained from the Japanese Red Cross.
Statistical analysis
Trends in mortality can be characterized by one or more of three
types of effects: age, period, and cohort.9,10 Age effects are
present for virtually every cause of death. Period effects
typically occur as a result of changes affecting all age groups—
for example, changes in diagnostic standards and cure rates, and
introduction of an aetiologic agent with a rapid effect. Cohort
effects typically occur when people born at a given time are
more exposed to an agent as compared with people born at
another time.
Age- and sex-specific mortality rates were calculated and
tested for trends.11 We then carried out two types of regression
analysis. First, to assess both overall trends and trends within
each 5-year period, we estimated age-standardized rate and
annual percentage change for each 5-year period. We employed
a log-linear Poisson regression model to estimate annual
percentage change, in which age groups and calendar years
were included as independent variables:
(1)
where Dij and Nij are, respectively, the number of deaths and
the size of the population in age group i in time period j, and αi
represents the effect of age group i and βj the effect of time
period j. Second, despite its popularity in the assessment of
chronic diseases, separate effects due to age, period, and cohort
for mortality rates of a particular disease can hardly be
quantified by a three-factor multiplicative model (i.e. age-
period-cohort model) because of the non-identifiability problem
arising from the linear relationship among the three
factors.12–14 Possible solutions have been proposed, including
the use of individual-level data, the application of other
covariates in place of either period or cohort variable, and some
mathematical constraints to a model.14 In the present study, we
employed the first two approaches to avoid the problem. Since
the trends in liver cancer morbidity and mortality are strongly
related to changes in hepatitis infection,15,16 we used the
incidence of post-transfusion hepatitis as a covariate in place of
the period variable in the second Poisson regression model:17
(2)
where PREVj denotes the continuous variable of incidence of
post-transfusion hepatitis in time period j and γk denotes
the effect of birth cohort k. Both models were then fit to the
data by maximum likelihood methods. Person-years at risk
were approximated by the size of the mid-year population
in each year.
Results
Figure 1 represents age- and sex- specific mortality rates of
hepatocellular carcinoma (HCC) from 1972 to 2001. There was
a statistically significant increase in mortality rates among males
aged 65 and over. On the contrary, mortality rates in younger
age groups have started to decrease since the 1980s. Female
mortality rates showed a less clear trend, but a steady increase
in mortality among older age groups was also observed
since 1992–96.
In both sexes, the number of deaths from HCC increased
substantially during the past three decades and the mortality
from HCC among men almost tripled (Table 1). Overall trends
of age-specific mortality rates are summarized by age-
standardized mortality rates and annual percentage changes in
mortality. Male mortality rates, age-standardized to the 1990
population, increased by 70% over the past two decades from
17.4 per 100 000 in 1972–76 to 29.6 per 100 000 in 1992–96,
but decreased slightly in the subsequent period. On the other
hand, female age-standardized mortality from HCC showed a
slight increase during the past three decades. Mortality rates for
liver cirrhosis showed a substantial decline in both sexes since
the 1970s: male and female mortality rates decreased from 27.0
and 10.9 per 100 000 in 1972–76 to 9.8 and 4.2 per 100 000
in 1997–2001, respectively. The trends of age-standardized
mortality rates were confirmed with the annual percentage
changes in mortality rates. Among males, the annual
percentage change in age-adjusted mortality rates of HCC
was approximately 1–4% through the period 1972–96 with a
subsequent decline in 1997–2001. On the other hand, the
change among females was not significant, except for a
substantial increase in the early 1990s and with a subsequent
decline in 1997–2001. Both absolute and percentage changes of
mortality were not parallel for HCC and liver cirrhosis in both
sexes during the entire period from 1972 to 2001.
After adjusting for age and period effects, the cohort effect of
mortality risk from HCC is estimated from Equation (2). For
example, the risk of mortality among birth cohorts born in
1952–56 relative to the reference cohort born in 1882–86 is:
Figure 2 shows
the estimated relative risks of mortality from HCC for each birth
cohort in a logscale. In both sexes, there was a peak in mortality
risk for the cohorts born during 1927–36, which corresponded to
those aged 50–64 years in 1987–91 and those aged 55–
69 years in 1992–96, respectively. This increasing trend in cohort
effects before the mid-1930s is consistent with a large increase of
both age-specific mortality rates among older age groups and
exp(195256)/exp(188286) exp(1952561).
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age-standardized mortality rates for the period 1986–96, in
particular among males. The levels of mortality risks in both
sexes levelled off and continued to decline for the cohorts born
thereafter and the relative risk of HCC mortality returned to the
levels before the study period among those born after 1955.
Discussion
HCC is one of the most common malignancies in the world,
predominantly affecting the developing regions where the hepatitis
virus is endemic.18 Over the past two decades, however, an
increase in mortality and morbidity from HCC has been observed
in industrialized countries.1–3 The numbers of deaths due to HCC
increased significantly in Japan over the past three decades, from
51 000 to 153 000, and its age-standardized mortality rate of HCC
is the highest among industrialized countries.19
It should be noted, however, that several factors other than
changes in actual mortality have an influence on the secular
trends of HCC mortality, including changes in: classification
and coding, diagnostic techniques and ascertainment, age
distribution, and survival from the disease.1,2,6–8 Although
primary liver cancer may be recorded in the mortality statistics
rather than a definitive diagnosis HCC or hepatoblastoma in the
eighth and ninth revisions of the International Classification of
Diseases and Related Health Problems (ICD), the vast majority
of primary liver cancer in Japan is HCC and the proportion of
hepatoblastoma and misclassified metastatic liver tumours is
very small.16 In addition, age-standardized rates of primary
liver cancer did not change according to the revision of ICD
classification systems. Thus, the effects of any changes in coding
and the disease classification system are likely to have been very
small and unable to bias seriously the trends over time.
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Figure 1 Age-specific mortality rates of hepatocellular carcinoma in Japan, 1972–2001
Males
0
20
40
60
80
100
120
140
160
180
20-24 25-29 30-34 35-39 40-44 45-49 50-54 55-59 60-64 65-69 70-74 75-80 80-84 85-89
Age group
Ag
e-
sp
ec
ific
 m
or
ta
lity
 ra
te
 p
er
 1
00
00
0
Females 
0
10
20
30
40
50
60
70
80
90
20-24 25-29 30-34 35-39 40-44 45-49 50-54 55-59 60-64 65-69 70-74 75-80 80-84 85-89
Age group
Ag
e-
sp
ec
ific
 m
or
ta
lity
 ra
te
 p
er
 1
00
00
0
1972-76 1977-81 1982-86 1987-91 1992-96 1997-2001
400 INTERNATIONAL JOURNAL OF EPIDEMIOLOGY
Table 1 Mortality from hepatocellular carcinoma and liver cirrhosis in Japan, 1972–2001
Hepatocellular carcinoma Liver cirrhosis
Age-standardized Annual percentage Total number Age-standardized Annual percentage Total number
Period mortality ratea change (95% CI) of deaths mortality ratea change (95% CI) of deaths
Males
1972–76 17.4 1.8b (1.0–2.5) 32 335 27.0 0.7b (0.1–1.3) 52 428
1977–81 20.7 4.2b (3.5–4.9) 45 176 25.9 1.2b (1.8 to 0.6) 58 472
1982–86 25.3 3.3b (2.7–3.9) 63 966 23.0 2.8b (3.4 to 2.3) 59 240
1987–91 28.5 1.1b (0.6–1.6) 83 485 19.4 2.4b (3.0 to 1.8) 56 999
1992–96 29.6 1.6b (1.1–2.0) 100 560 15.6 9.6b (10.2 to 9.1) 51 348
1997–2001 27.4 2.7b (3.1 to 2.3) 109 365 9.8 11.4b (12.1 to 10.8) 36 174
Females
1972–76 10.0 2.4b (3.4 to 1.4) 18 167 10.9 2.1b (3.1 to 1.2) 20 229
1977–81 9.6 0.6 (1.6 to 0.4) 20 602 10.1 1.0b (1.9 to 0.0) 22 039
1982–86 9.4 0.1 (0.9 to 1.0) 23 960 9.5 1.0b (1.9 to 0.1) 24 452
1987–91 9.6 0.8 (0.1 to 1.6) 28 935 8.6 1.7b (2.6 to 0.8) 25 976
1992–96 10.2 3.0b (2.3 to 3.8) 36 331 6.7 12.1b (12.9 to 11.3) 23 319
1997–2001 10.6 0.8b (1.4 to 0.1) 43 871 4.2 6.1b (7.1 to 5.1) 16 978
aRates are age-standardized to the 1990 population and per 100 000 populations.
bP  0.05 for the null hypothesis that the annual per cent change is equal to zero.
The changes might have been an artefact of improvements in
diagnosis, which would provide a more accurate picture of
mortality trends. In particular, substantial improvements in the
detection of liver cancer in cirrhotic patients can be expected
through the introduction of new diagnostic techniques, and a
shift of death certification from cirrhosis to liver cancer would
affect HCC mortality significantly.2 However, the routine use of
ultrasonography and serum alpha-fetoprotein since the early
1980s in cirrhotic patients could not explain continuously
increasing trends of mortality from 1982 to 1996. The annual
increase in the liver cancer mortality rate and the annual decline
in cirrhotic mortality were not parallel for the past three decades
in both sexes. Other possible factors would include changes in
prognosis of treated HCC. However, the recent studies have
consistently shown improvements in overall survival rates of
HCC,20 which contradict currently observed mortality trends.
Although HCC predominantly affects the elderly populations in
industrialized countries, ageing alone cannot explain the rising
mortality from HCC as shown by the trends of age-specific
mortality rates. The rise in age-specific mortality in the older
groups was coupled with an initial increase and subsequent
reduction in mortality among younger age groups. If the overall
mortality were the reflection of an ageing population, one would
expect an increase in mortality that is either restricted to or out of
proportion, among persons in the older age groups, irrespective
of when they were born.1 On the other hand this trend is most
probably the result of the exposure to risk factors, which affect all
birth cohorts but are stronger in cohorts born during a certain
period. In fact, the present study has confirmed an upward trend
of mortality from HCC in Japan due to the effects of birth cohorts
born around the 1930s, which have contributed to a large
increase in mortality from HCC in the recent years.
Among the histologically confirmed HCC, the majority of
cases were due to hepatitis C virus as reported by others.16,21
Although hepatitis B virus (HBV) is more common in many
parts of Asia, the relative importance of hepatitis C virus (HCV)
as a cause of HCC has been significantly increased in Japan after
the introduction of HBV screening in 1972 and nearly 90% of
hepatocellular carcinoma is now caused by HCV.5,15,21–23 One
possible explanation is that the trends of the cohort effects are
consistent with the pattern of past exposure to hepatitis viruses.
In fact, the cohort effect in both sexes showed a similar pattern,
with a peak for the cohorts born during 1927–36. These
cohorts corresponded to those aged 50–64 years in 1987–91
and those aged 55–69 years in 1992–96, in which the highest
prevalence of HCV among the voluntary blood donors
was observed.24–26 For example, Tanaka and colleagues
investigated 197 600 voluntary blood donors aged 15–64 years
residing in Osaka in the early 1990s and found that the
prevalence of anti-HCV antibody was significantly higher in
the blood donors aged 55–64 years than in those aged 16–
54 years (8.5 vs 1.3% among males; 7.3 vs 1.4% among
females).25 The age pattern of HCV prevalence was consistent
with the latest study on 3.5 million pooled blood donors during
1995–2000.26 For the cohorts born after the 1950s, the risk of
mortality from HCC decreased rapidly and we would expect a
further mortality decline due to the introduction of HCV
screening in 1989.24,27
The majority of the study populations are the cohorts born
before 1950, which were under 50 years of age during the
1950s and 1960s. This was exactly the time when illicit
intravenous drug abuse (i.e. meta-amphetamine addiction) was
endemic in Japan and, according to the official statistics, more
than 5% of the population aged 15–25 years were drug
abusers.28 The spread of hepatitis viruses, particularly HCV,
from drug abusers to the general population was most likely
due to transfusion of unscreened or commercial blood and
blood products and medical practices (e.g., needle sharing for
immunizations).19,24,29,30 In fact, before commercial blood was
replaced by screened and voluntarily donated blood in 1969,
the probability of developing post-transfusion hepatitis reached
nearly 50%. Since the cohorts born around the 1930s was
about 10–30 years of age during the 1950s and 1960s, their risk
of becoming infected with hepatitis viruses was high, as
suggested by the cohort risk of mortality from HCC. Since there
is an approximately 30-year time lag between exposure to
hepatitis viruses and liver cancer,31,32 those infected with
hepatitis viruses during the 1950s or 1960s would develop HCC
in the 1980s and 1990s, during which period mortality from
HCC rapidly increased in Japan.
Due to the ecological nature of the current analysis, however,
the interpretation of the results should be made with caution.33
For example, cohort effects would also reflect unobserved
factors other than exposure to the HCV. Further studies would
be needed to assess the plausibility of the inference made above.
Although the horizontal and vertical transmissions of HBV
and of HCV have been substantially reduced since the
introduction of blood screening, there are still 2–3 million
carriers infected with hepatitis viruses,29 the majority of which
are infected with HCV. The number of deaths from HCC is
expected to increase by 2010–15 since it was only after the
cohorts born around 1950 and thereafter that the relative risks
of HCC mortality returned to the levels before the study period.
It is suggested that approximately 2–7% of all patients with
chronic HCV will develop HCC.1,34,35 Responding to the public
awareness of a rapid increase in mortality and morbidity from
HCV infection, the Japanese Government has recently
implemented the population-based screening programme of
anti-HCV antibody in housewives and elderly people outside
workforces aged between 40 and 70 years. Further analysis of
the future trends of mortality and incidence of HCC and other
consequences of chronic HCV infection is required to test
whether the programme should be targeted at the general
public over the age of 40 or those at a higher risk including
haemodialysis and haemophilia patients, and recipients of blood
or blood products before 1992.29,30
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Figure 2 Relative risk of mortality from hepatocellular carcinoma by birth cohort in Japan (in a log-scale, reference birth cohort = 1882–1886)
KEY MESSAGES
• In both sexes, there was a considerable increase in age-standardized mortality rates from hepatocellular carcinoma
(HCC) during the period 1972–2001 in Japan.
• An upward trend of mortality from HCC in Japan was primarily due to the effects among birth cohorts born around
1930, which are consistent with the pattern of past exposure to hepatitis C virus.
• Birth cohort effects have contributed to a large increase in mortality from HCC in recent years and the number of deaths
from HCC is expected to increase by 2010–15.
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